

Accepted Manuscript

Efficacy of Ponatinib versus Earlier-Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia

Elias Jabbour, MD, Maral DerSarkissian, PhD, Mei Sheng Duh, ScD, MPH, Nora McCormick, MSc, Wendy Y. Cheng, MPhil, MPH, Lisa J. McGarry, MPH, Ariadne Souroutzidis, BA, Hui Huang, PhD, MBA, Susan O'Brien, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD

PII: S2152-2650(17)31872-4

DOI: [10.1016/j.clml.2018.02.010](https://doi.org/10.1016/j.clml.2018.02.010)

Reference: CLML 1070

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 5 December 2017

Revised Date: 9 February 2018

Accepted Date: 13 February 2018

Please cite this article as: Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM, Efficacy of Ponatinib versus Earlier-Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.02.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Comparative Efficacy of Ponatinib versus Earlier-Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia

Elias Jabbour, MD^{*a}; Maral DerSarkissian, PhD^b; Mei Sheng Duh, ScD, MPH^b; Nora McCormick, MSc^b; Wendy Y. Cheng, MPhil, MPH^b; Lisa J. McGarry, MPH^c; Ariadne Souroutzidis, BA^b; Hui Huang, PhD, MBA^c; Susan O'Brien, MD^d; Farhad Ravandi, MD^a; Hagop M. Kantarjian, MD^a

^a *University of Texas MD Anderson Cancer Center, Houston, TX, USA*

^b *Analysis Group, Inc., 111 Huntington Ave, 14th Floor, Boston, MA, USA*

^c *ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA*

^d *Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA*

*Corresponding Author: Elias Jabbour, MD

Affiliation: University of Texas MD Anderson Cancer Center

Mailing address: 1515 Holcombe Blvd #207, Houston, TX 77030

Telephone: (713) 792-7305

Email: EJabbour@mdanderson.org

Co-authors:

Maral DerSarkissian, PhD

Email: Maral.DerSarkissian@analysisgroup.com

Mei Sheng Duh, ScD, MPH

Email: Mei.Duh@analysisgroup.com

Nora McCormick, MSc

Email: Nora.McCormick@analysisgroup.com

Wendy Y. Cheng, MPhil, MPH

Email: Wendy.Cheng@analysisgroup.com

Lisa J. McGarry, MPH

Email: mcgarry.nagar@gmail.com

Ariadne Souroutzidis, BA

Email: asouroutzidis@gmail.com

Hui Huang, PhD, MBA

Download English Version:

<https://daneshyari.com/en/article/8615506>

Download Persian Version:

<https://daneshyari.com/article/8615506>

[Daneshyari.com](https://daneshyari.com)